MOTS-c peptide is a mitochondrial-derived peptide under investigation for insulin sensitivity in prediabetes, but it has no approved human drug product and its marketed fat-loss benefits remain unbacked by completed clinical trials. At Longevity Benchmark, we evaluate peptide research against registered clinical trial records and federal regulatory dockets so buyers can distinguish tested medical applications from online marketing claims.
The Verdict
Biological Classification of MOTS-c Peptide
MOTS-c peptide is a mitochondrial-derived peptide under investigation for insulin sensitivity rather than an approved weight-loss drug or growth hormone. Official clinical registry records define the molecule as a mitochondrial-derived peptide, abbreviated as MDP. It is not a GLP-1 receptor agonist. It is not a growth hormone or growth-hormone secretagogue.
GLP-1 receptor agonists and growth hormones are different classes of molecule. Online distributors frequently group these molecules together in commercial catalogs. This practice misleads buyers who expect GLP-1 weight loss. In registered clinical investigations, scientists evaluate MOTS-c strictly for insulin sensitivity in prediabetes.
Reasons for Confusion with GLP-1 Receptor Agonists
Commercial confusion between MOTS-c peptide and glucagon-like peptide-1 receptor agonists stems from overlapping target study populations rather than shared biological mechanisms. The registered Phase 2a trial tests MOTS-c in adults with prediabetes, insulin resistance, and overweight or obesity. Because MOTS-c is being studied in the same population GLP-1 drugs are, consumers assume MOTS-c provides comparable effects.
That assumption is scientifically unsupported. MOTS-c is not a GLP-1 receptor agonist. Instead, researchers study its role as a mitochondrial-derived peptide. Assuming that MOTS-c produces GLP-1 weight loss represents a major misconception. Buyers evaluating metabolic health can review clinical distinctions in our analysis of insulin resistance vs prediabetes.
Federal Regulatory Status of MOTS-c Peptide
MOTS-c peptide has no approved human drug product and is excluded from federal bulk compounding allowance lists. The Food and Drug Administration (FDA) tracks bulk drug substances that may present safety risks in human compounding. On that public docket, the FDA places MOTS-c under bulk drug substances nominated but withdrawn. Nominators withdrew their submissions. This withdrawal removes MOTS-c from active compounding consideration.
It does not sit on any list of bulk substances permitted for pharmacy compounding. The same withdrawn table includes BPC-157, CJC-1295, epitalon, and injectable GHK-Cu. It also includes melanotan II, PEG-MGF, selank acetate, semax, thymosin alpha-1, and TB-500. Federal documentation updated through 22 April 2026 confirms that no clinical safety clearance exists for these withdrawn substances. We detail these federal compounding policies in our guide to peptide therapy FDA status.
Clinical Trial Parameters for MOTS-c Peptide
Only one interventional clinical trial evaluating MOTS-c peptide as a drug product exists on the federal registry. That trial is registered on ClinicalTrials.gov under the identifier NCT07505745. Its official title is 'A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c (a Mitochondrial-Derived Peptide) in Adults With Prediabetes and Overweight/Obesity.' Hudson Biotech sponsors the study. Investigators plan to enroll an estimated 120 adult participants.
The protocol evaluates prediabetes, insulin resistance, and overweight or obesity. The official study registry record specifies subcutaneous injection as the investigated administration route. Study recruitment began across clinical sites on 2 February 2026. The registry lists primary completion on 14 February 2027. The study status is recruiting.
| Trial Parameter | Registered Protocol Detail | Clinical Significance |
|---|---|---|
| Study Identifier | NCT07505745 | Sole interventional drug trial on the registry |
| Official Title | Phase 2a study in prediabetes and overweight/obesity | Specifies MOTS-c as a mitochondrial-derived peptide |
| Study Sponsor | Hudson Biotech | Commercial biotechnology sponsor |
| Trial Phase | Phase 2a randomized double-blind trial | Early efficacy and pharmacodynamics evaluation |
| Enrollment Target | 120 adult participants | Estimated participant enrollment |
| Investigated Conditions | Prediabetes, insulin resistance, overweight/obesity | Focuses on insulin sensitivity rather than fat loss |
| Administration Route | Subcutaneous injection | Official route recorded for clinical evaluation |
| Trial Timeline | Started 2 February 2026; completion 14 February 2027 | Results remain unposted while recruitment continues |
| Current Status | Recruiting | No human efficacy or safety data published |
Unstudied Consumer Claims for Fat Loss and Muscle
Commercial claims that MOTS-c peptide burns adipose tissue, increases lean muscle mass, or slows human aging have no backing in published clinical trials. Online vendors frequently advertise the molecule for physique transformation. No interventional study tests those outcomes. The only active trial on the federal registry evaluates insulin resistance and prediabetes. Other MOTS-c entries on the registry are observational studies rather than drug trials.
One observational project evaluated platelet reactivity, beta-amyloid, MOTS-c, and mortality in type 2 diabetic patients with coronary artery disease. Other trials measured circulating mitochondrial-derived peptides as biomarkers following exercise. None of those studies administered MOTS-c as a therapeutic drug. As of October 2026, no completed human efficacy trial of MOTS-c has posted results. The same registry gap runs through our reviews of KPV peptide evidence and BPC-157 evidence, and peptide therapy cost covers what clinics charge for compounds in this category.
Conditions Required to Alter the Evidence Assessment
We will change this assessment when a randomized controlled trial publishes completed, peer-reviewed efficacy and safety data. Today the verdict rests on what the trial registry shows. The active Phase 2a trial NCT07505745 has a registered primary completion date of 14 February 2027. If Hudson Biotech completes that trial and reports verified improvements in insulin sensitivity, our assessment would change. The study must also demonstrate an acceptable safety profile across its 120 adult participants.
Until those verified results appear, MOTS-c remains an unproven compound. This peptide is not for individuals seeking weight loss, muscle enhancement, or general longevity interventions. Those goals are unsupported by registered clinical data. People seeking metabolic improvement should use established dietary protocols, exercise regimens, or approved medications under clinical supervision. We discuss another unapproved compound with incomplete clinical data in our guide to DSIP peptide evidence.
Clinical Alternatives and Validated Metabolic Testing
Patients concerned about insulin sensitivity can measure validated clinical biomarkers through accredited diagnostic laboratories rather than using unapproved peptides. Clinicians evaluate insulin regulation through fasting insulin measurements. They also calculate the homeostatic model assessment of insulin resistance (HOMA-IR) score.
A licensed healthcare provider can interpret these findings within standard clinical guidelines. If metabolic dysfunction is identified, clinicians recommend evidence-based therapies with established safety profiles. Schedule a comprehensive metabolic blood panel with a licensed clinician to measure verified insulin biomarkers before considering an unapproved research compound like MOTS-c peptide.
Frequently Asked Questions
What is MOTS-c peptide used for?
In clinical research, scientists are studying MOTS-c peptide for insulin sensitivity in adults with prediabetes and overweight or obesity. A registered Phase 2a trial sponsored by Hudson Biotech is currently evaluating its effects on insulin resistance and pharmacodynamics. In contrast, online vendors market MOTS-c peptide for fat loss, muscle growth, and longevity enhancement. These commercial applications have no backing in published human clinical trials. No regulatory agency has approved MOTS-c peptide for any medical condition or wellness goal.
Is MOTS-c peptide safe?
The human safety profile of MOTS-c peptide remains clinically unverified because no completed clinical safety trials have posted results. The only registered interventional drug trial evaluating the compound in humans began recruiting in February 2026 and lists a primary completion date in February 2027. Furthermore, the Food and Drug Administration lists MOTS-c among bulk drug substances nominated but withdrawn from compounding consideration, providing no clinical safety clearance. Without completed Phase 2 safety data, the risks, side effects, and systemic consequences of administering MOTS-c peptide to humans remain unknown.
Is MOTS-c peptide approved?
MOTS-c peptide is not approved by the Food and Drug Administration or any other medical regulatory authority. There are no approved prescription drugs or over-the-counter medications containing MOTS-c on the market. In addition, federal regulators exclude MOTS-c from lists of bulk drug substances permitted for pharmacy compounding. Nominators originally requested compounding consideration but subsequently withdrew their submissions. Consequently, MOTS-c is not on any list of bulk substances permitted for compounding, and federal documentation provides no clinical safety clearance.
Is MOTS-c peptide a GLP-1?
MOTS-c peptide is not a glucagon-like peptide-1 (GLP-1) receptor agonist. It belongs to an entirely separate molecular classification known as mitochondrial-derived peptides. MOTS-c is being studied for its effects on insulin sensitivity. While both are studied in populations with overweight or prediabetes, they are entirely different classes of molecule.
Is MOTS-c peptide a growth hormone?
MOTS-c peptide is not a growth hormone and is not a growth-hormone secretagogue. These represent different classes of molecules. MOTS-c is classified as a mitochondrial-derived peptide.
Does MOTS-c peptide work?
Whether MOTS-c peptide works in humans cannot be verified because no completed human efficacy trials exist as of October 2026. The sole interventional drug trial on ClinicalTrials.gov, designated NCT07505745, is currently recruiting 120 adult participants with prediabetes and insulin resistance. That study will evaluate efficacy endpoints against a placebo, with primary completion scheduled for February 2027. Other registered studies involving MOTS-c are purely observational biomarker evaluations. Until placebo-controlled trial results are formally published, scientific proof that MOTS-c works as a therapeutic agent in humans does not exist.
Does MOTS-c peptide help with weight loss?
There is no published human clinical evidence demonstrating that MOTS-c peptide promotes weight loss or fat reduction. Online marketing claims describing MOTS-c as a fat-loss peptide extrapolate far beyond registered scientific research. The only active interventional clinical study is evaluating insulin sensitivity, safety, and pharmacodynamics in adults with prediabetes, not body composition or adipose tissue loss. Consumers seeking weight loss should consult a licensed healthcare professional to evaluate established nutritional, exercise, and approved medical therapies supported by human clinical trial data.
What does MOTS-c peptide do for the body?
The physiological effects of administering MOTS-c peptide to the human body are currently under formal investigation. In clinical research, scientists are evaluating whether subcutaneous administration of MOTS-c improves insulin sensitivity in adults with prediabetes and insulin resistance. Outside of this registered Phase 2a trial, observational studies merely measure natural circulating levels of MOTS-c in relation to cardiovascular disease, diabetes, or exercise response. Peer-reviewed data establishing what therapeutic administration of MOTS-c does to human tissue remain unavailable until clinical trials conclude.